Replimune Group
REPL • NASDAQ
Replimune Group is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Sushil Patel, with a market cap of $596.2M.
CEOSushil Patel
Next Earnings
Upcoming earnings announcement for Replimune Group
Date
Thursday, May 21, 2026 (in 2 months)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q4 2026
EPS Estimate
-$0.75
Revenue Estimate
$12.6M
Earnings History
Past 12 earnings reports for Replimune Group
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 3, 2026 | Q3 2026 | -$0.77Est: -$0.83 | +7.2% | -Est: $3.2M | -100.0% |  10-Q |
| Nov 6, 2025 | Q2 2026 | -$0.90Est: -$0.82 | -9.8% | -Est: $500.0K | -100.0% | 10-Q |
| Aug 7, 2025 | Q1 2026 | -$0.95Est: -$0.82 | -15.9% | -Est: $3.2M | -100.0% | 10-Q |
| May 22, 2025 | Q4 2025 | -$0.82Est: -$0.69 | -18.8% | - | — | 10-K |
| Feb 12, 2025 | Q3 2025 | -$0.79Est: -$0.75 | -5.3% | - | — | 10-Q |
| Nov 12, 2024 | Q2 2025 | -$0.68Est: -$0.78 | +12.8% | - | — | 10-Q |
| Aug 8, 2024 | Q1 2025 | -$0.78Est: -$0.85 | +8.2% | - | — | 10-Q |
| May 16, 2024 | Q4 2024 | -$0.82Est: -$0.79 | -3.8% | - | — | 10-K |
| Feb 8, 2024 | Q3 2024 | -$0.77Est: -$0.93 | +17.2% | - | — | 10-Q |
| Nov 7, 2023 | Q2 2024 | -$0.90Est: -$0.86 | -4.7% | - | — | — |
| Aug 3, 2023 | Q1 2024 | -$0.75Est: -$0.85 | +11.8% | - | — | 10-Q |
| May 18, 2023 | Q4 2023 | -$0.74Est: -$0.69 | -7.2% | - | — | — |